CRISPR Therapeutics and Vertex Pharmaceuticals NEWS
CRISPR Therapeutics (CRSP) announced the completion of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of Sickle Cell Disease (SCD) in people ages 12 and older with recurrent vaso-occlusive crises (VOCs).
Exa . . .